US 9,314,483 B2Granted

Human monocyte sub-population for treatment of central nervous system injury

AssigneeYeda Research and Development Co. Ltd.

InventorsMichal Eisenbach-Schwartz, Ester Yoles, Ravid Shechter, Omer Miller

Life of this patent

Estimating the term…

Abstract

A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and optionally of CD16+ cells, for use in treatment of CNS injury is provided.

Claims10

Dependent claims

A method for treating a CNS injury comprising injecting into the CSF of an individual in need an effective amount of a subpopulation of peripheral blood mononuclear cells (PBMCs) substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and CD16+ cells.

Dependencies are inferred from the claim text.

Facts

Application: 14/303,212Filed 12 Jun 2014 · continuation
Priority: 14 Dec 2011
Published: US 2014/0363411 A111 Dec 2014
Granted: 19 Apr 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 35/14
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61K 40/17
Characterised by the cell type used: monocytes; Macrophages
A61K 40/24
Characterised by the effect or the function of the cells: antigen-presenting cells [APC]
A61K 40/414
Vertebrate antigens: nervous system antigens

Family

Application61/570,593Us provisional application · filed 14 Dec 2011
PCT/IL2012/050522Parent of this continuation · filed 13 Dec 2012
US 2014/0363411 A1Pre-grant publication · published 11 Dec 2014
US 9,314,483 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results